Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Novel Role for Alpha-2-Macroglobulin (A2M) as a Disease Modifying Protein in Senile Osteoporosis

ABSTRACT: Identification of the downregulation of A2M in bone marrow isolated from elderly (24-month-old) vs mature (3-month-old) mice.

ORGANISM(S): Mus musculus

PROVIDER: GSE243475 | GEO | 2023/10/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Novel role for alpha-2-macroglobulin (A2M) as a disease modifying protein in senile osteoporosis

Project description: Not available

| S-EPMC10642388 | biostudies-literature

Novel Role for Alpha-2-Macroglobulin (A2M) as a Disease Modifying Protein in Senile Osteoporosis

Project description:Novel Role for Alpha-2-Macroglobulin (A2M) as a Disease Modifying Protein in Senile Osteoporosis

| PRJNA1018558 | ENA

Investigate A2M treatment in liver of mice

Project description:Cancer resistance is a major cause for longevity of the naked mole-rat. Recent liver transcriptome analysis in this animal compared to wild-derived mice revealed higher expression of alpha2-macroglobulin (A2M) and cell adhesion molecules, which contribute to the naked mole-rat’s cancer resistance. Notably, A2M is known to dramatically decrease with age in humans. We hypothesize that this might facilitate tumour development. Here we found that A2M modulates tumour cell adhesion, migration and growth by inhibition of tumour promoting signalling pathways, e.g. PI3K / AKT, SMAD and up-regulated PTEN via down-regulation of miR-21, in vitro and in tumour xenografts. A2M increases the expression of CD29 and CD44 but did not evoke EMT. Transcriptome analysis of A2M-treated tumour cells, xenografts and mouse liver demonstrated a multifaceted regulation of tumour promoting signalling pathways indicating a less tumorigenic environment mediated by A2M. By virtue of these multiple actions the naturally occurring A2M has strong potential as a novel therapeutic agent.

2018-01-30 | GSE107194 | GEO

Investigate A2M treatment on human prostate cancer xenograft in mice

Project description:Cancer resistance is a major cause for longevity of the naked mole-rat. Recent liver transcriptome analysis in this animal compared to wild-derived mice revealed higher expression of alpha2-macroglobulin (A2M) and cell adhesion molecules, which contribute to the naked mole-rat’s cancer resistance. Notably, A2M is known to dramatically decrease with age in humans. We hypothesize that this might facilitate tumor development. Here we found that A2M modulates tumor cell adhesion, migration and growth by inhibition of tumor promoting signalling pathways, e.g. PI3K / AKT, SMAD and up-regulated PTEN via down-regulation of miR-21, in vitro and in tumor xenografts. A2M increases the expression of CD29 and CD44 but did not evoke EMT. Transcriptome analysis of A2M-treated tumor cells, xenografts and mouse liver demonstrated a multifaceted regulation of tumor promoting signalling pathways indicating a less tumorigenic environment mediated by A2M. By virtue of these multiple actions the naturally occurring A2M has strong potential as a novel therapeutic agent.

2018-01-25 | GSE106989 | GEO

Transcriptome profiling of A2M treated A549 Cell Line Samples

Project description:The goal of the study was to identify changes in transcriptome expressions upon treatment of A549 cell line samples with activated A2M.

2018-01-23 | GSE106261 | GEO

Bone formation in senile osteoporosisbone formation in senile osteoporosis

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-08-03 | GSE210426 | GEO

Expression data from human CD34+ HPC subpopulations transduced with nuclear-trapped AF1q/MLLT11 (A2M)

Project description:We used microarrays to examine the impact of AF1q/MLLT11 on the gene expression profile of CD34+CD45RA-Lin- and CD34+CD45RA+Lin- HPCs isolated from umbilical cord blood CD34+CD45RA-Lin- and CD34+CD45RA+Lin- HPCs correspond respectively to early multipotent and lympho-granulo-macrophagic precursors. A2M is a nuclear mutant-derivative of AF1q/MLLT11 CD34+CD45RA-Lin- and CD34+CD45RA+Lin- HPCs were FACS-sorted, exposed to A2M or control vectors, sorted based on GFP expression, and subjected to global gene expression analysis 72 hrs later.

2011-05-26 | E-GEOD-29523 | biostudies-arrayexpress

Expression data from Notch-activated CD34+CD45RA-Lin- hematopoietic progenitor cells (HPCs) transduced with nuclear-trapped AF1q/MLLT11 (A2M)

Project description:We used microarrays to examine the impact of AF1q/MLLT11 on the gene expression profile of Notch-activated CD34+CD45RA-Lin- HPCs isolated from umbilical cord blood CD34+CD45RA-Lin- HPCs correspond to early multipotent progenitors. A2M is a nuclear mutant derivative of AF1q/MLLT11 CD34+CD45RA-Lin- HPCs were FACS-sorted, exposed to A2M or control vectors, sorted again based on GFP expression, and cultured for 72 hrs with graded doses of plastic-immobilized Notch ligand Delta1ext-IgG

2011-05-26 | E-GEOD-29524 | biostudies-arrayexpress

The Transcriptomic Analysis of Profibrinolytic (PLAUR) and Fibrinolytic Inhibitor (SERPINE1, A2M) Genes in COVID-19 Patients and Its Relationship with D-Dimer Levels

Project description:There is a statistically significant difference in the expression of the PLAUR and fibrinolytic inhibitor genes (SERPINE1, A2M) in mild and moderate-to-severe cases. There is a relationship between serum D-dimer levels and the expression of the PLAUR and fibrinolytic inhibitor genes (SERPINE1, A2M).

2024-09-14 | GSE259214 | GEO

Investigate A2M treatment in liver of mice

Project description:Investigate A2M treatment in liver of mice

| PRJNA419257 | ENA